Can Mounjaro Cause Transaminitis?
Yes, Mounjaro (tirzepatide) can cause transaminitis and clinically significant liver injury, though this appears to be a rare adverse effect. While the FDA label does not specifically list transaminitis as a common adverse reaction, emerging case reports document hepatocellular injury ranging from mild transaminase elevations to severe acute liver injury requiring hospitalization 1, 2, 3, 4.
Evidence from FDA Labeling
The official FDA prescribing information for Mounjaro does not list transaminitis among the common adverse reactions in placebo-controlled trials 5. The label focuses primarily on gastrointestinal side effects (nausea, vomiting, diarrhea), hypoglycemia risk, and gallbladder disease. However, the absence from the label does not preclude occurrence, as postmarketing surveillance continues to identify rare hepatic events.
Emerging Clinical Evidence
Multiple case reports from 2024-2026 document tirzepatide-associated liver injury with varying severity:
Severe hepatocellular injury has been reported approximately 5 weeks after initiation, particularly following dose escalation. One case achieved a RUCAM score of 7 (indicating "probable" drug-induced liver injury) after excluding viral, autoimmune, metabolic, and biliary causes 1.
Acute hepatitis developed in a 76-year-old woman after 8 weeks of use with sixteen-pound weight loss, confirmed by liver biopsy as drug-induced liver injury 2.
A systematic review of 43 tirzepatide adverse event cases identified liver injury as one of the notable manifestations, with acute liver injury not mentioned in the drug instructions. Among liver injury cases assessed by RUCAM, 2 were rated "possible" and 1 was "probable" 6.
Transaminitis with rhabdomyolysis has been documented, with significantly elevated transaminase levels alongside elevated creatine kinase 7.
Clinical Pattern and Risk Factors
The hepatotoxicity appears to follow these patterns:
- Timing: Most cases occur within 1-6 months of initiation, often shortly after dose escalation 1, 6, 4
- Presentation: Ranges from asymptomatic transaminase elevation to symptomatic hepatocellular injury with jaundice, dark urine, and gastrointestinal symptoms
- Biochemical pattern: Predominantly hepatocellular injury, though mixed and cholestatic patterns have been reported 1
- Potential modifiers: Rapid weight loss, dose escalation, and concurrent hepatotoxic medications may increase susceptibility 1, 6
Mechanism
The mechanism remains uncertain but likely represents an idiosyncratic drug reaction rather than dose-dependent toxicity 1, 2. Rapid weight loss and hepatic steatosis mobilization may act as susceptibility modifiers rather than direct causes.
Paradoxical Hepatic Benefits
Importantly, tirzepatide generally improves liver health in metabolic dysfunction-associated steatotic liver disease (MASLD). Guidelines note that GLP-1 receptor agonists decrease hepatic fat, reduce liver enzymes, and improve liver histology in most patients 8. The SYNERGY-NASH trial suggests tirzepatide may promote resolution of steatohepatitis 9. This creates a clinical paradox where the drug typically benefits the liver but rarely causes injury.
Clinical Recommendations
When prescribing tirzepatide:
Baseline liver function tests should be obtained before initiation
Monitor liver enzymes at 1-3 months after starting therapy and after dose escalations, particularly in patients with:
- Concurrent hepatotoxic medications
- Rapid weight loss (>10 kg in first month)
- Pre-existing liver disease
Discontinue immediately if patients develop:
- Unexplained jaundice or dark urine
- Severe or persistent abdominal pain with elevated transaminases
- Transaminases >3-5× upper limit of normal without alternative explanation
Enhanced monitoring is warranted in patients taking multiple medications affecting hepatic metabolism 6
Common Pitfall
Do not dismiss new-onset gastrointestinal symptoms as typical GLP-1 side effects if they occur beyond the initial dose escalation period or are accompanied by systemic symptoms (fatigue, dark urine, jaundice). These may herald hepatotoxicity rather than benign GI intolerance 4.
The clinical significance is that while transaminitis from tirzepatide is rare, it can be severe and requires vigilance, particularly during the first 6 months of therapy and following dose escalations.